The Opioid Use Disorder market growth is driven by factors like increase in the prevalence of Opioid Use Disorder, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Opioid Use Disorder market report also offers comprehensive insights into the Opioid Use Disorder market size, share, Opioid Use Disorder epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Opioid Use Disorder market size growth forward.
Some of the key highlights from the Opioid Use Disorder Market Insights Report:
- Several key pharmaceutical companies, including BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals, and others, are developing novel products to improve the Opioid Use Disorder treatment outlook.
- The total Opioid Use Disorder market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Opioid Use Disorder market is anticipated to witness growth at a considerable CAGR
- The total prevalent cases of Opioid Use Disorder (OUD), in the 7MM, were approximately 3,971,300 cases in 2022 and are projected to increase during the forecast period (2023-2032).
- The total market size of Opioid Use Disorder (OUD) in the United States was approximately USD 1,370 million in 2022 and is projected to grow during the forecast period (2023–2032).
Strategise your business goals by understanding market dynamics @ Opioid Use Disorder Market Landscape
Opioid Use Disorder Overview
Repeated substance use that creates problems in a person’s home, work, or school life is defined as a Substance Use Disorder (SUD), a treatable mental health condition. The United States loses nearly 185 people every day to substance overdose deaths. Opioids are involved in almost 70% of the lives lost due to substance overdoses, equating to nearly 47,000 opioid-related deaths in 2018 alone. Opioid Use Disorder (OUD) is a type of SUD defined by the repeated use of opioids. The economic burden of OUD and fatal opioid overdose is estimated to be over one billion dollars annually in the US when accounting for healthcare and treatment, criminal justice, lost productivity, reduced quality of life, and value of life lost costs. OUD significantly impacts the lives of individuals who experience OUD, families and loved ones, and communities nationwide.
Opioid Use Disorder (OUD) Diagnosis
A diagnosis is based on specific criteria such as unsuccessful efforts to cut down or control use, as well as use resulting in social problems and a failure to fulfill obligations at work, school, or home. The term opioid use disorder superseded the phrases opioid abuse and opioid dependence in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The DSM-5 assesses the severity of opioid use disorder based on the frequency of recurrent symptoms reported during the previous 12 months.
Opioid Use Disorder (OUD) Treatment
Drug therapy for Opioid Use Disorder (OUD) has been linked to lower overdose and overall fatality rates. Buprenorphine, methadone, and naltrexone are all FDA-approved drugs for the treatment of Opioid Use Disorder (OUD). Clinicians should provide or organize therapy using evidence-based drugs for individuals suffering from Opioid Use Disorder (OUD), especially if the condition is moderate or severe. Clinicians who are unable to treat patients with Opioid Use Disorder (OUD) should refer them to a substance use disorder treatment specialist, such as an office-based buprenorphine or naltrexone treatment provider, or an opioid treatment program certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) to provide methadone or buprenorphine for patients with Opioid Use Disorder (OUD).
Do you know the treatment paradigms for different countries? Download our Opioid Use Disorder Market Sample Report
Opioid Use Disorder Epidemiology Segmentation
DelveInsight’s Opioid Use Disorder market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Opioid Use Disorder historical patient pools and forecasted Opioid Use Disorder patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Opioid Use Disorder Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Opioid Use Disorder Prevalence
- Age-Specific Opioid Use Disorder Prevalence
- Gender-Specific Opioid Use Disorder Prevalence
- Diagnosed and Treatable Cases of Opioid Use Disorder
Visit for more @ Opioid Use Disorder Epidemiological Insights
Opioid Use Disorder Treatment Market
There are effective therapies for Opioid Use Disorder (OUD); however, only roughly one in every four persons with OUD receives specialized care. Medication for opioid use disorder (MOUD), known as the “gold standard” of therapy, is an evidence-based treatment for those suffering from OUD. Counseling and behavioral treatments may be an essential aspect of treatment in addition to drugs, but they are not successful on their own. Medications are also used to treat cravings, alleviate withdrawal symptoms, and prevent opioid euphoria. These drugs do not “cure” the illness; rather, they increase safety and decrease withdrawal symptoms, which might lead to relapse or ongoing drug use. Methadone, buprenorphine, and naltrexone are three FDA-approved drugs often used to treat opioid use disorder (OUD).
Methadone, an oral µ-agonist, has been widely used and extensively researched around the world. Methadone is exclusively available in the United States through licensed and tightly regulated clinics that initially need practically daily patient involvement to acquire the medicine, however, occasional take-home doses are normally permitted for patients who follow program criteria.
Patients must have a current opioid-use disorder with physiologic characteristics or be at high risk of relapse to be eligible for methadone maintenance. Furthermore, individuals are not already enrolled in another maintenance program and are not particularly prone to methadone-related medical issues.
The limitation of methadone to specialized clinics in the United States has led to the hunt for an alternative oral, long-acting opioid. This search has led to the discovery of buprenorphine maintenance treatment. Although oral buprenorphine is rapidly degraded in the liver, it is efficiently absorbed when administered as a sublingual tablet or buccal film. Buprenorphine’s effects extend for 24 to >36 h. It alleviates opioid withdrawal symptoms and somewhat inhibits other opioid intoxication. Overdoses are a concern with buprenorphine, especially when used with depressant medications, and drug diversion is a possibility. However, mortality with buprenorphine induction is lower than during methadone induction.
Naltrexone is a µ-opioid receptor antagonist that inhibits opioid effects and aids in the maintenance of opioid abstinence in highly motivated patients. Medication therapy is most successful when combined with patient engagement in a self-help group as part of a cognitive behavioral approach (to increase motivation, work towards behavioral improvements, and prevent relapse). At larger dosages, these drugs might cause gastrointestinal discomfort, tiredness, sleeplessness, and abnormal levels of liver function tests. However, naltrexone is reasonably safe for those who drink a lot of alcohol and those who have hepatitis C or HIV.
The treatment of Opioid Use Disorder (OUD) differs as per geography. In contrast to other nations that have established harm reduction measures for OUD, treatment of OUD has not been licensed in Japan, making opioid maintenance therapy challenging, and detoxification is only provided at a few mental facilities.
The ‘Narcotics and Psychotropics Control Act’ in Japan severely regulates opioid analgesics. Furthermore, because Japanese physicians prescribe fewer opioids, Japan has not seen the huge surge in opioid usage seen in other nations. As a result, many Japanese physicians believe that opioid analgesic overuse or addiction is uncommon in Japan.
Because few viable medicines are being studied to control OUD, it is fair to assume that the therapeutic space will undergo considerable reconfiguration between 2023 and 2032.
A few players like Braeburn Pharmaceuticals (CAM2038), BioXcel Therapeutics (BXCL501), and others are evaluating their lead candidates for the treatment of Opioid Use Disorder (OUD). These therapies are expected to change the Opioid Use Disorder (OUD) treatment landscape.
Opioid Use Disorder Key Companies
- Indivior PLC
- Alkermes
- Orexo AB
- Titan Pharmaceuticals
- Teva Pharmaceutical Industries Ltd
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc
- Viatris
- Pfizer
- Hikma Pharmaceuticals
- Camurus
Opioid Use Disorder Therapy Assessment
SUBLOCADE: Indivior
SUBLOCADE includes buprenorphine, a partial opioid agonist, and is approved for the treatment of moderate to severe opioid use disorder in patients who have started therapy with a transmucosal buprenorphine product, followed by dosage modification for at least 7 days. SUBLOCADE should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.
Buprenorphine is now approved for use in the treatment of OUD as a pill, film that dissolves in the mouth, or implant. SUBLOCADE is a novel therapeutic option for people in recovery who may appreciate the advantages of a once-monthly injection over other forms of buprenorphine, such as the ease of taking medicine daily.
VIVITROL (Naltrexone)
VIVITROL is an opioid antagonist. Opioid-dependent individuals, including those being treated for alcoholism, must be opioid-free for the first VIVITROL dose. VIVITROL should be used in conjunction with a complete management program that includes psychological assistance. The drug was approved in October 2010, by the US FDA to prevent relapse to opioid dependence following opioid detoxification.
For more information, visit Opioid Use Disorder Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Opioid Use Disorder Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Opioid Use Disorder, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Opioid Use Disorder epidemiology in the 7MM
- Opioid Use Disorder marketed and emerging therapies
- Opioid Use Disorder companies
- Opioid Use Disorder market drivers and barriers
Key Questions Answered in the Opioid Use Disorder Market Report 2032:
- What was the Opioid Use Disorder market share distribution in 2019, and how would it appear in 2032?
- What is the total Opioid Use Disorder market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Opioid Use Disorder market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Opioid Use Disorder market projected to expand at 7MM?
Table of Contents:
1 Opioid Use Disorder Market Key Comprehensive Insights
2 Opioid Use Disorder Market Report Introduction
3 Competitive Intelligence Analysis for Opioid Use Disorder
4 Opioid Use Disorder Market Analysis Overview at a Glance
5 Executive Summary of Opioid Use Disorder
6 Opioid Use Disorder Epidemiology and Market Methodology
7 Opioid Use Disorder Epidemiology and Patient Population
8 Opioid Use Disorder Patient Journey
9 Opioid Use Disorder Treatment Algorithm, Opioid Use Disorder Current Treatment, and Medical Practices
10 Key Endpoints in Opioid Use Disorder Clinical Trials
11 Opioid Use Disorder Marketed Therapies
12 Opioid Use Disorder Emerging Therapies
13 Opioid Use Disorder: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Opioid Use Disorder
16 Opioid Use Disorder Market Key Opinion Leaders Reviews
18 Opioid Use Disorder Market Drivers
19 Opioid Use Disorder Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Opioid Use Disorder Epidemiology 2032
DelveInsight’s “Opioid Use Disorder – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Opioid Use Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Opioid Use Disorder Pipeline 2023
“Opioid Use Disorder Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Opioid Use Disorder market. A detailed picture of the Opioid Use Disorder pipeline landscape is provided, which includes the disease overview and Opioid Use Disorder treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/